Delving into the Latest Updates on Meningococcal A/C vaccine(Hualan Biological Bacterin Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

A群C群脑膜炎球菌多糖疫苗, Group A and C Meningococcal Polysaccharide Vaccine

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesNervous System Diseases

Active Indication

EncephalomyelitisMeningitis

Inactive Indication

Meningococcal Infections

Originator Organization

Hualan Biological Vaccine, Inc.

Active Organization

Hualan Biological Vaccine, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (12 Mar 2018),

Encephalomyelitis

Regulation-

Login to view timeline

BACKGROUND AND OBJECTIVESNeisseria meningitidis is transmitted from person-to-person. Thus, close contact with a healthy carrier can facilitate the spread of the bacteria and lead to life-threatening meningococcal disease. The aim of this study was to identify oropharyngeal carriers of N. meningitidis in volunteers preparing for military service before vaccination.MATERIALS AND METHODSIn a cross-sectional study, 226 volunteers entering military service were referred to the Shemiranat Health Center for meningococcal vaccination and assayed. Before vaccination, the participants underwent sampling of the throat using separate swabs. Thayer-Martin Agar medium and microbiological standard methods were used for culture and isolation of the organisms. The bacterial isolates were subjected to DNA extraction and polymerase chain reaction. The obtained data were descriptively analyzed.RESULTSOut of the 226 (100%) young volunteers, only 18 (8%) yielded Gram-negative diplococci. The results showed the presence of N. meningitidis (carriage rate: 8%) in their oropharyngeal regions. The isolated serogroups were C, A, Y, W-135, and X with frequencies of 50, 22.2, 16.6, 5.5, and 5.5, respectively.DISCUSSIONThis study showed that the carriage rate in young volunteers for military service is around 8% before vaccination. Although the rates for serogroups A and C were dominant, the existence of serogroups Y and W indicate the necessary revision of the A/C vaccine. More research is needed to determine serogroup diversity and decrease the risk of meningococcal disease in individual groups.

01 May 2014·Emerging Infectious DiseasesQ2 · MEDICINE

Carriage Rate and Effects of Vaccination after Outbreaks of Serogroup C Meningococcal Disease, Brazil, 2010

Q2 · MEDICINE

ArticleOA

Author: Bricks, Lucia Ferro ; Sáfadi, Marco Aurelio Palazzi ; Sato, Helena Keico ; Sacchi, Claudio Tavares ; Gorla, Maria Cecilia Outeiro ; Cassio de Moraes, José ; Fukasawa, Lucila O. ; Gonçalves, Maria Gisele ; Ribeiro, Ana Freitas ; Higa, Fabio ; Brandileone, Maria Cristina Cunto ; Carvalhanas, Telma Regina Marques Pinto ; Paula de Lemos, Ana ; Salgado, Maristela

During 2010, outbreaks of serogroup C meningococcal (MenC) disease occurred in 2 oil refineries in São Paulo State, Brazil, leading to mass vaccination of employees at 1 refinery with a meningococcal polysaccharide A/C vaccine. A cross-sectional study was conducted to assess the prevalence of meningococci carriage among workers at both refineries and to investigate the effect of vaccination on and the risk factors for pharyngeal carriage of meningococci. Among the vaccinated and nonvaccinated workers, rates of overall meningococci carriage (21.4% and 21.6%, respectively) and of MenC carriage (6.3% and 4.9%, respectively) were similar. However, a MenC strain belonging to the sequence type103 complex predominated and was responsible for the increased incidence of meningococcal disease in Brazil. A low education level was associated with higher risk of meningococci carriage. Polysaccharide vaccination did not affect carriage or interrupt transmission of the epidemic strain. These findings will help inform future vaccination strategies.

01 Jan 2014·Journal of Infectious DiseasesQ2 · MEDICINE

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population

Q2 · MEDICINE

Article

Author: Timo Vesikari ; Hartmut J. Ehrlich ; Eva Maria Pöllabauer ; Thomas R. Kreil ; M. Keith Howard ; Otfried Kistner ; Daniel Portsmouth ; P. Noel Barrett ; Maikel V. W. van der Velden ; Gerald Aichinger ; Bee Wah Lee ; Richard Fritz ; Thomas Dvorak ; Peter Richmond ; Sandor Fritsch ; Javier Diez-Domingo

BACKGROUNDChildren are highly vulnerable to infection with novel influenza viruses. It is essential to develop candidate pandemic influenza vaccines that are safe and effective in the pediatric population.METHODSInfants and children aged 6-35 months and 3-8 years, respectively, were randomized to receive 2 immunizations with a 7.5-µg or 3.75-µg hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years received a 7.5-µg dose only. A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later. HA and neuraminidase antibody responses were assessed.RESULTSVaccination was safe and well tolerated; adverse reactions were transient and predominantly mild. Two immunizations with the 7.5-µg dose of A/Vietnam vaccine induced virus microneutralization (MN) titers of ≥1:20 against the A/Vietnam strain in 68.8%-85.4% of participants in the different age groups. After the booster, 93.1%-100% of participants achieved MN titers of ≥1:20 against the A/Vietnam and A/Indonesia strains. Neuraminidase-inhibiting antibodies were induced in ≥90% of participants after 2 immunizations with the 7.5 µg A/Vietnam vaccine and in 100% of participants after the booster.CONCLUSIONSA whole-virus influenza A(H5N1) vaccine is suitable for prepandemic or pandemic immunization in a pediatric population.CLINICAL TRIALS REGISTRATIONNCT01052402.

100 Deals associated with Meningococcal A/C vaccine(Hualan Biological Bacterin Co., Ltd.)

Login to view more data